Lyophilization USA Conference 2018

SMi Group15 - 16 November 2018, New Jersey, USA.
16% of the top 100 pharmaceutical drugs and 35% of biologic drugs are lyophilized. With more than 30% of the FDA-approved parenterals lyophilized and soon more than half injectable drugs to require lyophilization there is ample room for standardization and expansion of the lyophilization process in pharmaceuticals.

The 4th Annual Lyophilization USA conference will be analysing technological advantages, regulatory challenges and unmet needs within lyophilization.

Day 1 of the Conference (November 15) will be covering Novel Techniques and Advances, Regulatory Challenges and Analytical Processes; Continuous monitoring of sublimation rate for individual containers & Reconstitution challenges of lyophilized highly concentrated protein products; Freeze dryer characterization and application to drug product development and scale up; Formulation and excipient selection for lyo product development of vaccines

Day 2 of the Conference (November 16) will be focusing on challenges that process of lyophilization brings to pharmaceutical and biotechnology companies; Oncobiologics on Freezing of biologics formulations - impact on stability; Panel Discussion on Process modelling and simulation; and also looking into alternatives to conventional methods with the Keynote Address on vacuum-foam drying and key action points on future directions in lyophilization

Featured Speakers

  • Alex Langford - Pfizer
  • Colin Campbell - Elusys Therapeutics
  • Dena Flamm - Optima Machinery Corporation
  • Fabrice Schlegel - Amgen
  • Hiten Gutka - Oncobiologics
  • Morrisa Jones - Merck
  • Alina Alexeenko - Purdue University
  • Rui Fang - Merck Research Laboratories
  • Sushma Kommareddy - Takeda
  • Timothy McCoy - Sanofi

Enhance your knowledge on controlled nucleation, available PAT's and the future of flexible PAT processes, and alternative freeze dryer technologies including spray drying, spin freeze-drying and microwave drying at the Workshop A on November 14 hosted by Alexander Tambovzev and Dena Flamm of Optima Pharma

Are you new to the area of freeze-drying/lyophilization? Sign up to attend the Workshop B on November 14 hosted by Robin Bogner, University of Connecticut and gain an understanding of the essential aspects of freeze-drying.

Further details at http://www.lyophilization-usa.com/wpnWL

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...